| 0.2966 -0.079 (-21.12%) | 03-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.46 |
1-year : | 0.56 |
| Resists | First : | 0.39 |
Second : | 0.48 |
| Pivot price | 0.36  |
|||
| Supports | First : | 0.25 |
Second : | 0.2 |
| MAs | MA(5) : | 0.35 |
MA(20) : | 0.33 |
| MA(100) : | 0.64 |
MA(250) : | 1.41 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 37.5 |
D(3) : | 45.4 |
| RSI | RSI(14): 41.1 |
|||
| 52-week | High : | 3.31 | Low : | 0.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NOTV ] has closed above bottom band by 13.9%. Bollinger Bands are 36.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.39 - 0.39 | 0.39 - 0.39 |
| Low: | 0.29 - 0.29 | 0.29 - 0.3 |
| Close: | 0.29 - 0.3 | 0.3 - 0.3 |
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Wed, 18 Mar 2026
Inotiv (NOTV) price target decreased by 12.12% to 4.93 - MSN
Wed, 11 Mar 2026
Inotiv Secures Temporary Waiver on Credit Agreement Liquidity Covenant - The Globe and Mail
Tue, 10 Mar 2026
Lenders grant Inotiv (NASDAQ: NOTV) brief liquidity covenant waiver - Stock Titan
Mon, 09 Feb 2026
Inotiv Inc. (NASDAQ:NOTV) Reports Q1 Revenue Miss and Widened Loss, Shares Drop - ChartMill
Wed, 04 Feb 2026
Drug research firm Inotiv plans Q1 2026 results call Feb. 9 - Stock Titan
Wed, 03 Dec 2025
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 34 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 12.8 (%) |
| Held by Institutions | 22.6 (%) |
| Shares Short | 2,020 (K) |
| Shares Short P.Month | 1,970 (K) |
| EPS | -1.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.17 |
| Profit Margin | -13.5 % |
| Operating Margin | -13.4 % |
| Return on Assets (ttm) | -3.2 % |
| Return on Equity (ttm) | -49.8 % |
| Qtrly Rev. Growth | 0.8 % |
| Gross Profit (p.s.) | 3.51 |
| Sales Per Share | 14.94 |
| EBITDA (p.s.) | 0.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.16 |
| PEG Ratio | 0 |
| Price to Book value | 0.09 |
| Price to Sales | 0.01 |
| Price to Cash Flow | -0.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|